Lung cancer in women is a critical women’s health issue in the United States. An average of 181 women die each day of lung cancer—one every 8 minutes. In fact, two-thirds of the never-smoked lung cancer population is female. Why does the number of young women with lung cancer who have never smoked continue to rise? There is no clear answer, but we’re working to make sure research into this issue remains a priority. Last year, The NELSON Trial revealed women [...]
TAKE ACTION! Through consistent advocacy efforts, GO2 Foundation (formerly Lung Cancer Alliance) established the Lung Cancer Research Program (LCRP) within the Congressionally Directed Medical Research Programs, administered by the Department of Defense with federal appropriations of $20 million in Fiscal Year (FY) 2009. LCRP has been underfunded the past 10 years, below its original $20 million dollars level. Congress must restore the funding level back to $20 million this year. Since FY09 and through FY18, the program has been funded [...]
The GO2 Foundation for Lung Cancer is honored to announce that on May 2 two of our programs received Your Cancer’s Cancer Community (C2) Awards. These awards celebrate “the unsung heroes of cancer care”—individuals and organizations that advance cancer care and work to improve the lives of those living with the disease. The Centers of Excellence (COE) program received Your Cancer’s C2 Catalyst for Care Award. This category recognized nominees making the experience of cancer care easier for patients. We [...]
Each year, more than 1.8 million people receive a lung cancer diagnosis. Though research and treatment options have come a long way, there is still far more work to be done to stop the number one cancer killer. The Lung Cancer Registry was created for anyone who has been diagnosed with lung cancer to allow patients to be a part of the solution. The registry is a knowledge base for lung cancer researchers working to find medical treatments through data shared [...]
On April 11, the U.S. Food and Drug Administration approved pembrolizumab (KEYTRUDA) as a first-line treatment for patients with advanced NSCLC who have a score of 1% or higher on the PD-L1 biomarker test. The approval was based on KEYNOTE-042 trial which demonstrated statistically significant OS improvements for those randomized to pembrolizumab compared with chemotherapy. Click here to read the full press release.
The LCA Science and Research team just returned from the 2019 Targeted Therapies of Lung Cancer Meeting, and we have good news: treatment options continue to expand in the targeted therapies and immunotherapy space to treat all types of lung cancer. Here’s what we learned. All of the advancements presented emphasize the importance of molecular testing/biomarker testing so that the best treatments can be chosen for a patient’s unique cancer. There are currently approved targeted therapies for patients whose cancers [...]
During the more than three years since our youngest daughter, Katherine, was diagnosed with Stage 4 non-small cell lung cancer, we have joined forces to advocate for more funding for lifesaving research into why so many young women get lung cancer every year. Here we are at last fall’s rally in front of the U.S. Capitol, where we joined hundreds of other survivors, friends and families to declare that lung cancer is a national emergency. By U.S. Congressman Rick [...]
Monday, June 4, 2018 --Today, Lung Cancer Alliance (LCA) is proud to announce Carl M. Gay, MD, PhD as the recipient of the 2018 Conquer Cancer Foundation of ASCO/Lung Cancer Alliance Young Investigator Award (YIA). Through this award, LCA will support Dr. Gay’s research into whether inhibiting DNA repair mechanisms in small cell lung cancer can either lead to cancer death or increase the ability for immunotherapies to work better to fight the cancer. Conquer Cancer Foundation formally announced the [...]